Eagle Pharmaceuticals Inc (EGRX.OQ)
EGRX.OQ on NASDAQ Stock Exchange Global Market
61.99USD
16 Oct 2018
61.99USD
16 Oct 2018
Change (% chg)
-- (--)
-- (--)
Prev Close
$61.99
$61.99
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
89,813
89,813
52-wk High
$85.66
$85.66
52-wk Low
$48.94
$48.94
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Jun '18 | 59.30 | 0.172 |
| Mar '18 | 46.63 | 0.169 | |
| FY 2017 | Dec '17 | 46.78 | 0.801 |
| Sep '17 | 63.02 | 0.979 | |
| Jun '17 | 50.11 | 0.280 | |
| Mar '17 | 76.79 | 1.418 | |
| FY 2016 | Dec '16 | 81.14 | 3.530 |
| Sep '16 | 37.83 | 0.727 | |
| Jun '16 | 40.92 | 0.796 | |
| Mar '16 | 29.59 | -0.057 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Dec-18 | 5 | 60.51 | 62.30 | 58.30 | 62.00 |
| Quarter Ending Mar-19 | 2 | 56.60 | 57.20 | 56.00 | -- |
| Year Ending Dec-18 | 5 | 221.57 | 228.10 | 217.10 | 214.92 |
| Year Ending Dec-19 | 5 | 245.57 | 257.80 | 236.55 | 281.67 |
| Earnings (per share) | |||||
| Quarter Ending Dec-18 | 5 | 1.33 | 1.53 | 1.09 | 1.21 |
| Quarter Ending Mar-19 | 1 | 1.18 | 1.18 | 1.18 | -- |
| Year Ending Dec-18 | 5 | 3.49 | 4.05 | 2.15 | 3.96 |
| Year Ending Dec-19 | 5 | 4.40 | 5.10 | 3.86 | 5.72 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | 9.78 | 30.95 | 32.69 | |
| P/E High - Last 5 Yrs. | -- | 40.57 | 45.21 | |
| P/E Low - Last 5 Yrs. | -- | 23.31 | 23.82 | |
| Beta | 1.23 | 0.89 | 0.88 | |
| Price to Sales (TTM) | 3.59 | 3.93 | 5.82 | |
| Price to Book (MRQ) | 5.34 | 4.78 | 4.90 | |
| Price to Tangible Book (MRQ) | 9.43 | 5.61 | 6.53 | |
| Price to Cash Flow (TTM) | 8.87 | 22.58 | 22.98 | |
| % Owned Institutions | -- | 1.13 | 2.14 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.58 | 1.51 | |
| Dividend Yield - 5 Year Avg | -- | 1.58 | 1.52 | |
| Dividend 5 Year Growth Rate | -- | 4.39 | 5.38 | |
| Payout Ratio(TTM) | 0.00 | 46.24 | 43.96 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 22.46 | 2.19 | 7.73 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 160.39 | 4.58 | 5.32 | |
| Sales - 5 Yr. Growth Rate | -- | 9.69 | 9.89 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -64.84 | 19.82 | 22.57 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 3,637.76 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 9.96 | 10.95 | |
| Capital Spending - 5 Yr. Growth Rate | -- | 15.12 | 14.94 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | 3.76 | 2.18 | 2.25 |
| Current Ratio (MRQ) | 3.88 | 2.97 | 3.05 |
| LT Debt to Equity (MRQ) | 0.00 | 9.93 | 12.63 |
| Total Debt to Equity (MRQ) | 0.00 | 13.92 | 16.96 |
| Interest Coverage (TTM) | -- | 41.53 | 37.54 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | 75.17 | 55.20 | 54.92 | |
| Gross Margin - 5 Yr. Avg. | -- | 52.31 | 52.45 | |
| EBITD Margin (TTM) | 33.38 | -- | -- | |
| EBITD - 5 Yr. Avg | -- | 18.46 | 11.10 | |
| Operating Margin (TTM) | 32.21 | 14.35 | 4.36 | |
| Operating Margin - 5 Yr. Avg. | -- | 14.35 | 6.45 | |
| Pre-Tax Margin (TTM) | 32.20 | 14.89 | 5.41 | |
| Pre-Tax Margin - 5 Yr. Avg. | -- | 14.80 | 6.89 | |
| Net Profit Margin (TTM) | 39.32 | 11.11 | 1.68 | |
| Net Profit Margin - 5 Yr. Avg. | -- | 11.07 | 3.14 | |
| Effective Tax Rate (TTM) | -22.12 | 23.35 | 23.23 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 23.58 | 24.11 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 3,193,182 | 912,999,537 | 812,879,200 | |
| Net Income/Employee (TTM) | 1,255,584 | 107,437,502 | 95,609,515 | |
| Receivable Turnover (TTM) | 4.67 | 5.63 | 5.78 | |
| Inventory Turnover (TTM) | 12.27 | 2.61 | 3.60 | |
| Asset Turnover (TTM) | 1.33 | 0.95 | 0.92 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | 52.32 | 11.37 | 10.94 | |
| Return on Assets - 5 Yr. Avg. | -- | 12.62 | 12.05 | |
| Return on Investment (TTM) | 64.07 | 14.77 | 14.32 | |
| Return on Investment - 5 Yr. Avg. | -- | 16.45 | 15.66 | |
| Return on Equity (TTM) | 70.78 | 16.27 | 16.04 | |
| Return on Equity - 5 Yr. Avg. | -- | 17.52 | 16.92 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | 186.11 | -- | -- |
| EPS (TTM) % | 3,033.35 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Eagle Pharmaceuticals Inc
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Eagle Pharmaceuticals Gets Final FDA Approval For Bendamustine Hydrochloride Ready-To-Dilute Solution In 500Ml Admixture
- BRIEF-Eagle Pharmaceuticals Reports Q1 Adjusted Non-GAAP Earnings Per Share Of $0.53
- BRIEF-Eagle Pharmaceuticals Says CEO Scott Tarriff's 2017 Total Compensation Was $8.04 Mln
Institutional Holders
| % Shares Owned: | 0.00% |
| # of Holders: | 254 |
| Total Shares Held: | 15,859,476 |
| 3 Mo. Net Change: | 65,332 |
| # New Positions: | 4 |
| # Closed Positions: | 2 |
| # Increased Positions: | 18 |
| # Reduced Positions: | 9 |
| # Net Buyers: | 9 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.